Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2/3 vs 6.
about
Hepatitis C genotype 6: A concise review and response-guided therapy proposalKASL clinical practice guidelines: management of hepatitis CHepatitis C virus genotype 6: virology, epidemiology, genetic variation and clinical implicationBest strategies for global HCV eradication.New antiviral therapies for chronic hepatitis CIncreased prevalence of hepatitis C virus subtype 6a in China: a comparison between 2004-2007 and 2008-2011.Correlation of viral loads with HCV genotypes: higher levels of virus were revealed among blood donors infected with 6a strains.Meta-analysis: superior treatment response in Asian patients with hepatitis C virus genotype 6 versus genotype 1 with pegylated interferon and ribavirinEfficacy and safety of pegylated interferon plus ribavirin therapy for chronic hepatitis C genotype 6: a meta-analysis24 versus 48 Weeks of Peginterferon Plus Ribavirin in Hepatitis C Virus Genotype 6 Chronically Infected Patients with a Rapid Virological Response: A Non-Inferiority Randomized Controlled TrialEconomic evaluation of pegylated interferon plus ribavirin for treatment of chronic hepatitis C in Thailand: genotype 1 and 6.Response to Pegylated Interferon Plus Ribavirin in Patients with Hepatitis C Virus Genotype 6a Infection from Guangdong and Guangxi Province of China.High effectiveness of peginterferon alfa-2a plus ribavirin therapy in Korean patients with chronic hepatitis C in clinical practice.Racial Disparities in Treatment Rates for Chronic Hepatitis C: Analysis of a Population-Based Cohort of 73,665 Patients in the United States.Role of viral and host factors in interferon based therapy of hepatitis C virus infectionReal-world experience with interferon-free, direct acting antiviral therapies in Asian Americans with chronic hepatitis C and advanced liver disease.Systematic review: epidemiology of hepatitis C genotype 6 and its management.Systematic review: Asian patients with chronic hepatitis C infection.Impact of hepatitis C virus heterogeneity on interferon sensitivity: an overview.How to optimize hepatitis C virus treatment impact on life years saved in resource-constrained countries.Impact of IL28B and PNPLA3 polymorphisms on treatment outcomes in patients infected with genotype 6 hepatitis C virus.Meta-analysis of patients with hepatitis C virus genotype 6: 48 weeks with pegylated interferon and ribavirin is superior to 24 weeks.Hepatitis C virus genotypes circulating in patients with chronic hepatitis C in Thailand and their responses to combined PEG-IFN and RBV therapy.Prevalence of IL-28B and ITPA genotypes in Chinese Han population infected persistently with hepatitis C virus genotype 6 or HCV-1.Response-guided therapy for patients with hepatitis C virus genotype 6 infection: a pilot study.New insights into hepatitis C virus infection in the tribal-dominant part of Northeast India.Twenty-four weeks of pegylated interferon plus ribavirin effectively treat patients with HCV genotype 6a.KASL clinical practice guidelines: management of hepatitis C.Factors Associated with Health-Related Quality of Life in Korean Patients with Chronic Hepatitis C Infection Using the SF-36 and EQ-5D.2017 KASL clinical practice guidelines management of hepatitis C: Treatment of chronic hepatitis C
P2860
Q22305417-F50C58B4-4537-4124-8EA7-190B5DD5BF52Q26752471-0DC67CA9-B6FE-40AB-9EB0-12945ACDD79FQ27024231-C88E5D0E-27D3-4E3F-93E8-B50C670DE7E2Q27693824-C79CE990-8143-4865-945A-73C57DD0C063Q34130399-540F9048-7BBC-4A4E-9F3B-EC63215E5EF8Q34459438-01D639F9-C4F8-4888-ADD4-5DF94FADC2B5Q34533951-7BEFB95B-F903-42B8-81B7-9B94B9F33D3DQ35153869-B4C00AA7-0F30-443E-8E3D-52C72EFE7AB7Q35194590-0ADE4C68-206C-41B2-BB86-6B54C70C95B8Q35824222-FB441B38-A9C5-4D06-940D-08F1D9405207Q36095525-4AB592A3-86F3-463F-9B50-170C11F2F115Q36680950-26799D4D-3297-46B4-922E-DAA9C93B69FAQ36756380-8151F3B3-9B56-4612-B143-915E21CA2647Q36988702-D86187A1-E2B0-42C3-99C9-B9A033EAE8B0Q37362240-5EA8669F-C93C-40C4-ACB4-F201B0A04715Q37646759-BCCE9289-80F1-4F09-A7DC-B85BF9E6E755Q37882006-DB3B7F15-7B76-41A3-9F59-26478BE0F204Q38096012-B3D7EFAF-5A1E-4AF3-B0DE-57A7E582E1F2Q38224436-35566DC9-E012-40C3-93A9-4D1B3BAD133EQ39315196-12B79880-4F17-423A-9E32-769F7032DDC5Q41511393-42D234DE-2BDC-4F24-9E45-BFE49CD28AD9Q41556755-0994F490-7330-41EF-8CDF-F4DF438A5934Q42221723-C278B5CE-27CE-4FA6-86B9-998A4420690BQ42252312-9C66B585-CB61-4306-9516-8CDE7D87763DQ42980225-71BFBD77-A3DD-4008-8628-1B46B198572FQ42982178-06BF0763-1362-4A41-83C0-E08773EB0EF4Q43001742-98B2FC76-2BAC-4812-8A24-2AF20027A05CQ51836024-7AB4AC18-A96E-420F-8E2C-104EA037831CQ54247054-E56E5F74-DC18-4B2E-8FAA-83C95D7B9741Q58788714-35746DC3-720E-4AAD-AD15-CDF9FDBA94CF
P2860
Response to pegylated interferon and ribavirin in Asian American patients with chronic hepatitis C genotypes 1 vs 2/3 vs 6.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
Response to pegylated interfer ...... tis C genotypes 1 vs 2/3 vs 6.
@en
Response to pegylated interfer ...... tis C genotypes 1 vs 2/3 vs 6.
@nl
type
label
Response to pegylated interfer ...... tis C genotypes 1 vs 2/3 vs 6.
@en
Response to pegylated interfer ...... tis C genotypes 1 vs 2/3 vs 6.
@nl
prefLabel
Response to pegylated interfer ...... tis C genotypes 1 vs 2/3 vs 6.
@en
Response to pegylated interfer ...... tis C genotypes 1 vs 2/3 vs 6.
@nl
P2093
P1476
Response to pegylated interfer ...... tis C genotypes 1 vs 2/3 vs 6.
@en
P2093
M H Nguyen
N H Nguyen
R T Garcia
P2860
P304
P356
10.1111/J.1365-2893.2009.01226.X
P577
2010-10-01T00:00:00Z